Skip to main content
OpenTrials
Completed

NCT Number: NCT01364779

Prevalence of Aspirin Resistance in Chronic Kidney Disease Patients

The primary objective of the study is to determine the prevalence of aspirin resistance in chronic kidney disease patients. The secondary objectives are to determine possible risk factors contributing to aspirin resistance in this population.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Kidney Disease Chronic Disease Disease Attributes Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Male Urogenital Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency Renal Insufficiency, Chronic Urogenital Diseases Urologic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

staten island University Hospital nephrology clinic

Staten Island, New York, 10305, United States

About this study

A cross-sectional of "aspirin resistance in hemodialysis patients" previously done in our institution showed that 23/66 (34.7%) hemodialysis patients were aspirin resistant. In a recent systematic review, renal impairment was associated with aspirin resistance . This association was seen in only two out of the twenty studies used in this meta-analysis . Both these studies are from the same center with a predominant Asian population. In this study we will try to evaluate the prevalence of aspirin resistance in CKD patient without being limited to a specific ethnicity.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with known structural kidney disease as evident by history or by urinalysis and CKD stage III or IV determined by MDRD formula and who are taking aspirin.

Exclusion criteria

  • Younger than 18 years of age.
  • Bleeding disorder or myeloproliferative disorders.
  • Thrombocytopenia with platelets < 100.000.
  • Malignancy.
  • Acute hemorrhagic disease.
  • A recent history of receipt of platelet glycoprotein IIb/IIIa blockers.
  • Liver disease as evident by abnormal liver function and total bilirubin > 2mg/dl.
  • use of anticoagulation.

Treatment and study plan

Primary outcomes

  1. prevalence of aspirin resistance in chronic kidney disease patients

    Time frame: 2 years

    Blood drawn for the Accumetric test

Secondary outcomes

  1. risk factors contributing to aspirin resistance in this population.

    Time frame: 2 years

    risk factors

Sponsors and collaborators

Lead sponsor

Northwell Health

Other

Collaborators

  • Staten Island University Hospital

Registry information

Important dates

Study start
2010
Primary completion
2012
Study completion
2012
First posted
Jun 2, 2011
Registry last updated
May 15, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.